🔗 Share this article

A shadow market for unlicensed slimming drugs is being driven by TikTok fitness influencers and sellers on messaging platforms, according to new investigations.

Experimental Treatment Acquiring Traction Via Social Media

Retatrutide, which is still in research studies, is being advertised by social media influencers for its supposed weight-reducing properties. Viewers are urged to contact these accounts directly for supplier links, while also obtaining discount codes.

Thriving Commerce on Messaging Platforms

Additionally, a robust trade exists on Telegram, where groups with thousands of participants share comparison photos, administration instructions and claims of rapid British shipping. Sellers market the drug there before redirecting customers to WhatsApp for purchases.

Learning About Retatrutide

This medication is an investigational injection developed by American pharmaceutical company Eli Lilly. The drug targets three intestinal hormones – glucagon-like peptide-1, glucose-dependent insulinotropic polypeptide and pancreatic hormone. Early trials suggest it could assist individuals lose up to 25% of their total weight. Referred to as the “triple G”, the substance is being hailed digitally as the next Ozempic.

Healthcare Professionals Express Worries

However, physicians and pharmacists have cautions that the sale of what is still an unlicensed medication in the United Kingdom is a cause for concern and could lead to individuals administering products of uncertain source.

Some experts said the demand for retatrutide could be linked to the increasing cost of licensed weight loss products such as Mounjaro.

Legal Position and Enforcement

Selling the unapproved drug on social media or messaging apps is illegal in the United Kingdom, as it is an unapproved drug that must not be marketed or supplied for human use under the Human Medicines Regulations 2012.

Some influencers attempt to circumvent the rules by calling to the drug as a “research chemical” or citing it as “not for human consumption”. The substance is not a controlled substance, but advertising and distribution can still breach medicines, advertising, and customer laws, potentially leading to penalties, prosecution or prison.

Platform Response and Content Removal

According to the social media company, the service has removed problematic content and banned related keywords and search suggestions. The company stated it was dedicated to keeping the service secure and investing in strengthening compliance measures.

Online Marketplace Operations

Research also found groups with up to nine thousand members marketing the experimental drug using Telegram's built-in search feature, which functions like a online catalog. Entering “retatrutide” instantly brings up channels with numerous of members, populated with images of weight loss, glowing reviews and detailed guides for mixing or injecting at home.

Within moments of joining one community, a vendor posted contact information, where most purchases occur. The vendor sent an guidebook and guaranteed shipping within 48 hours. When questioned whether the substance was genuine, one vendor responded: “You can’t be sure.” Another provided a photo of a alleged testing documentation. Not one asked about body mass, medical conditions or past usage.

Product Information and Costs

Within these groups, posts show dark colored packages with Royal Mail stickers, claiming to contain fresh supplies. One communication read: “It took eight of us to load them this morning.”

Buyers can choose between dry substance containers, mixed at home with purified liquid, or ready-to-use pens typically priced at £160 for 20 milligrams. When questioned how much time a pen should be used, vendors give contradictory responses varying between a few weeks to “depends on your body”.

Platform Moderation and Safety Actions

A representative for the messaging service stated it actively monitored harmful material on its platform including content that encouraged the “misuse of controlled medications”. The organization noted that it eliminated “millions of pieces of harmful content each day”.

Medical Expert Cautions

“Individuals are injecting materials they cannot confirm. Although the science behind this drug is sound, these digital versions may not contain what they claim,” stated Jason Murphy, the head of pharmacy at a pharmacy service.

Dr Crystal Wyllie of an online medical service linked the increase in demand to current price rises for authorized weight-loss medications such as Mounjaro. “With costs increasing, patients are turning to online platforms. But counterfeit treatments are highly dangerous. You can’t be certain what’s contained or whether the environment they were produced in was clean,” she explained.

Her team has already encountered patients harmed by self-injection from unverified sources. “We recognize the frustration, but buying from messaging apps or communication platforms is taking chances with your well-being,” stated Wyllie. “These materials could be impure or improperly measured.”

Producer Statement

A spokesperson from Eli Lilly said the substance was in phase 3 research studies and had not been evaluated or authorized by any regulatory agency anywhere in the world. “Therefore at this point no one can market [it] for human use,” they explained, adding that any product “misleadingly claiming itself as a Lilly experimental substance not yet authorized … may expose patients to potentially serious health risks”.